Broncus Medical has introduced the new BioStar Transbronchial Aspiration Needle (TBNA) for minimally invasive diagnostic applications.
Medical professionals can use the new needle to obtain accurate tissue samples and quality specimens required for diagnosing and staging lung cancer.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The needle can seamlessly integrate with endobronchial ultrasound bronchoscopy (EBUS) procedures, improving clinical outcomes and patient care.
It has been designed to be used for both conventional TBNA (cTBNA) and EBUS-TBNA diagnostic techniques.
Broncus offers the needle in 21G, 22G and 25G configurations.
Featuring an advanced, ultra-thin design, the needle can reduce tissue disruption, increase accessibility and cut puncture force while ensuring comfort during sampling.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBy offering real-time visualisation, the needle allows clinicians to navigate complex anatomical structures with more accuracy.
The ergonomic handle design helps provide better manoeuvrability and enables seamless control, as well as precise placement of the needle during procedures.
The 21G BioStar EBUS needle features thin walls to better access nodes, which are difficult to reach while obtaining samples with a 19G needle.
Broncus Medical Europe sales and marketing senior director Christian Rumpf said: “Our commitment to advancing patient care and diagnostic accuracy has driven us to develop the BioStar TBNA Needle – a revolutionary tool that empowers medical professionals to make confident, informed decisions.”
BioStar is not approved for use in the US and is presently undergoing pre-market review by the US Food and Drug Administration.
